Search Results
Your search for The A matches 31879 pages
Showing 2251 - 2300There’s an App for That: Digital Health Solutions for Treating Insomnia in Cancer Survivors
Guest Editor’s Note: Insomnia is common in patients with cancer and cancer survivors, and it has significant negative consequences. Cognitive behavior therapy for insomnia (CBT-I) is an effective approach for managing insomnia but is not easily available to many patients. In this installment of The ...
Instinct and Perseverance Helped Save Me From Two Cancers
My intuition about my health has served me well over the past 10 years, possibly even saving my life from two serious cancers. In 2013, I was diagnosed with follicular lymphoma. I believe that my awareness of changes in my body led to its early discovery. One evening, after exercising at the gym...
Jesse M. Ehrenfeld, MD, MPH, Inaugurated as President of the AMA
Jesse M. Ehrenfeld, MD, MPH, was sworn in as the 178th President of the American Medical Association (AMA), the nation’s premier physician organization, on June 13, 2023. At his inauguration, Dr. Ehrenfeld spoke about health inequities and injustices: “The AMA has made tremendous strides in recent ...
Vivek Subbiah, MD, Joins SCRI to Advance Early-Phase Clinical Research
Sarah Cannon Research Institute (SCRI) recently announced that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development. In his role, Dr. Subbiah will oversee SCRI’s nine drug development units and lead the expansion of early-phase capabilities and programs across the...
Nicholas Petrelli, MD, FACS, Receives Lifetime Achievement Award From Tulane University Medical School
Nicholas Petrelli, MD, FACS, Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute in Newark, Delaware, has received the Lifetime Achievement Award from Tulane University School of Medicine in New Orleans. Dr. Petrelli is a 1973...
Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer
On August 2, 2023, the fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, was approved for use with bevacizumab for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based...
Addition of Nivolumab to Stereotactic Ablative Radiotherapy in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In a phase II trial (I-SABR) reported in The Lancet, Joe Y. Chang, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the addition of immunotherapy with nivolumab to stereotactic ablative radiotherapy (SABR) improved ...
Expert Point of View: Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, FACP, FASCO, the David H. Johnson Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, commented that the...
LEAP-017: No Significant Benefit for Lenvatinib Plus Pembrolizumab in Non–MSI-H/dMMR Metastatic Colorectal Cancer
In the final analysis of the phase III LEAP-017 study, the combination of lenvatinib plus pembrolizumab failed to improve outcomes over the standard of care in previously treated patients with metastatic colorectal cancer that lacked high microsatellite instability or mismatch repair deficiency...
Dostarlimab-gxly With Chemotherapy for Endometrial Cancer
On July 31, 2023, the immune checkpoint inhibitor dostarlimab-gxly was approved by the U.S. Food and Drug Administration (FDA) for use with carboplatin and paclitaxel, followed by single-agent dostarlimab, for patients with primary advanced or recurrent endometrial cancer that is mismatch...
Expert Point of View: Martina C. Murphy, MD
Discussant of the ENGOT-EN5/GOG-305/SIENDO trial, Martina C. Murphy, MD, Associate Professor of the Department of Medicine, Division of Hematology, University of Florida, shared insights on the topic of maintenance therapy, its effects on quality of life, and toxicity management. Dr. Murphy...
Selinexor Shows Activity as Maintenance Therapy for TP53 Wild-Type Endometrial Cancer in Phase III Trial
Long-term follow-up of selinexor maintenance therapy has demonstrated promising efficacy in patients with TP53 wild-type endometrial cancer, according to data presented during the ASCO Plenary Series: July 2023 Session.1 Selinexor is a selective inhibitor of nuclear export (SINE) approved for use...
Neoadjuvant Palbociclib Plus Giredestrant or Anastrozole in ER-Positive, HER2-Negative Breast Cancer
In a phase II study (coopERA Breast Cancer) reported in The Lancet Oncology, Sara A. Hurvitz, MD, and colleagues found that 2 weeks of the addition of neoadjuvant giredestrant—a novel nonsteroidal selective estrogen receptor (ER) degrader—to palbociclib showed a stronger antiproliferative effect...
Cytotoxic and Immune-Stimulatory Gene Therapy for Adults With Primary High-Grade Glioma
In a single-center, phase I, first-in-human trial reported in The Lancet Oncology, Yoshie Umemura, MD, and colleagues investigated treatment with the combination of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK) and Flt3L (Ad-hCMV-Flt3L) in adults with primary high-grade glioma. As stated...
Risk Factors for Incident Heart Failure Among Cancer Survivors Aged 18 to 39
In a study reported in a research letter in JACC: CardioOncology, Hibler et al found that survivors of young adult cancers who were exposed to anthracyclines were at an increased risk of subsequent diagnosis of heart failure. Study Details The study involved electronic health record data from the...
Dabrafenib Plus Trametinib in Relapsed or Refractory BRAF V600–Mutant Pediatric High-Grade Glioma
In a phase II trial reported in the Journal of Clinical Oncology, Hargrave et al found that dabrafenib plus trametinib was highly active in pediatric patients with relapsed or refractory BRAF V600–mutant high-grade glioma. Study Details In the trial, 41 previously treated patients (median age, 13...
Radiation Exposure From Medical Imaging in Pediatric Patients With Down Syndrome
Pediatric patients with Down syndrome may undergo almost 10 times as many medical imaging examinations as other pediatric patients, potentially exposing them to more ionizing radiation, according to a recent study published by Marlow et al in PLOS ONE. Background Ionizing radiation is present in...
Vitamin C and D Supplements for Patients With AML Undergoing Intensive Chemotherapy
Patients with acute myeloid leukemia (AML) who received vitamin C and D supplements during intensive chemotherapy had lower rates of complications such as infections, bleeding, and inflammation compared with patients who did not receive the supplements, according to a recent study published by...
ASCO Participates in President’s Cancer Panel Event
ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...
Nicholas J. Short, MD on Acute Lymphoblastic Leukemia: Phase II Findings on Mini-HCVD, Inotuzumab, and Blinatumomab
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses new data on improved outcomes in patients with relapsed or refractory acute lymphoblastic leukemia who received the combination of mini-HCVD and reduced-dose inotuzumab and then blinatumomab in sequence. In...
Efficacy of the 9-Valent HPV Vaccine: 10-Year Follow-up
New 10-year follow-up data were published by Restrepo et al in Pediatrics on girls and boys who received a three-dose regimen of the 9-valent human papillomavirus (HPV) vaccine between the ages of 9 and 15. The long-term follow-up study was conducted from 2009 through 2021 across 13 countries and 5 ...
Immune Checkpoint Inhibitors for Patients With Child-Pugh Class B vs A Advanced Hepatocellular Carcinoma
In a systematic review and meta-analysis reported in JAMA Oncology, Xie et al explored outcomes associated with immune checkpoint inhibition among patients with advanced hepatocellular carcinoma with Child-Pugh B vs Child-Pugh A liver function. Study Details The analysis included 22 studies...
High-Grade Serous Ovarian Cancer: Impact of Multimodal Screening on Survival
In an analysis of the UKCTOCS study reported in The Lancet Oncology, Menon et al found that patients with high-grade serous tubo-ovarian cancer detected on multimodal screening may have a survival benefit over those whose disease was diagnosed without screening. The investigator stated, “In...
Enhanced Recovery Program May Be Effective at Reducing Opioid Use After Pancreatic Cancer Surgery
Improving hospital care pathways may help reduce inpatient opioid use by 50% and cut the median opioid prescription volumes at discharge to zero in patients undergoing pancreatic cancer surgery, according to a recent study published by Boyev et al in JAMA Surgery. The new findings could help reduce ...
SNMMI Provides New Consensus Statement on LuPSMA Therapy
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has provided standardized guidance on the selection and management of patients receiving lutetium-177–labeled PSMA-617 (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer, according to a new consensus...
Nicholas J. Short, MD, on Acute Lymphoblastic Leukemia: New Analysis of Ponatinib and Blinatumomab
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase II study subgroup analysis that explored the question of whether ponatinib and blinatumomab, both active in Philadelphia chromosome–positive acute lymphoblastic leukemia, could offer an...
Is Cardiovascular Disease Linked to Increased Risk of Cancer?
In a retrospective cohort study reported in JACC: CardioOncology, Bell et al found individuals with a diagnosis of cardiovascular disease were more likely to have a subsequent cancer diagnosis than individuals with no cardiovascular disease diagnosis. Risk was elevated among persons with...
Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma
In a study reported in the Journal of Clinical Oncology, Mandelker et al found that pancreatic acinar cell carcinoma was associated with a high prevalence of BRCA2 germline pathogenic variants and genomic features of homologous recombination deficiency (HRD). The study involved somatic and germline ...
Allogeneic HCT Outcomes in Patients With MDS and High-Risk Genetics
In a genetic analysis from the Blood and Marrow Transplant Clinical Trials Network 1102 Study reported in the Journal of Clinical Oncology, Versluis et al found that allogeneic hematopoietic cell transplantation (HCT) improved overall survival compared with non-HCT treatment in patients with...
Phase III Trial Reports Chemoimmunotherapy Is Superior to Chemotherapy Alone in Malignant Pleural Mesothelioma
Patients with malignant pleural mesothelioma who were treated with a chemoimmunotherapy regimen containing the immune checkpoint inhibitor pembrolizumab experienced significantly improved overall survival compared with those treated with chemotherapy alone, with acceptable tolerability, according...
Nikhil Munshi, MD, on Multiple Myeloma: Data From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel
Nikhil Munshi, MD, of Dana-Farber Cancer Institute, discusses the final safety and efficacy results from the phase Ib/II CARTITUDE-1 trial of ciltacabtagene autoleucel. This CAR T-cell therapy targets B-cell maturation antigen in patients with relapsed or refractory multiple myeloma. Longer median...
Can AI Assessment of Screening Mammograms Offer Similar Accuracy to Human Readers?
A commercially available artificial intelligence (AI) algorithm may perform comparably to human readers at assessing screening mammograms, according to a recent study published by Chen et al in Radiology. False-positive interpretations on screening mammograms can result in women without cancer...
Examining Disparities in Endometrial Cancer Outcomes Among Black Patients
Black patients with stage IA low-grade endometrioid endometrial carcinoma may be less likely to undergo a hysterectomy and survive their cancer than White patients with the same type of cancer, according to a recent study published by Taylor et al in Gynecologic Oncology. Background “We’ve known...
Addition of Tumor Treating Fields Therapy to Standard Systemic Therapy in Metastatic NSCLC After Disease Progression
In a phase III trial (LUNAR) reported in The Lancet Oncology, Leal et al evaluated the addition of tumor treating fields therapy to standard systemic therapy in patients with metastatic non–small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. As stated by ...
Receptor Status Among Patients With Invasive Breast Cancer: What’s Missing?
In a study of SEER (Surveillance, Epidemiology, and End Results) data reported in JAMA Network Open, Stephens et al found that approximately 5% of patients with invasive breast cancer had missing components of receptor status and identified several factors associated with the lack of information....
Platinum-Sensitive Ovarian Cancer: Addition of Atezolizumab to Bevacizumab and Platinum-Based Therapy
In the phase III ATALANTE/ENGOT-ov29 trial reported in the Journal of Clinical Oncology, Kurtz et al found that the addition of atezolizumab to bevacizumab and platinum-based doublets did not significantly improve progression-free survival among patients with platinum-sensitive ovarian cancer....
23andMe Granted FDA 510(k) Clearance to Report Additional BRCA Variants
23andMe has announced that the company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be ...
Statins May Be Linked to Lower Risk of Colorectal Cancer in Patients With Ulcerative Colitis
Cholesterol-lowering statins may reduce colorectal cancer incidence and mortality in patients with ulcerative colitis, according to a recent study published by Sun et al in eClinicalMedicine. The findings also suggested that statin use may be associated with a lower risk of all-cause mortality in...
Strategies to Predict Immunotherapy Benefit Among Patients With Advanced Colorectal Cancer
Researchers have identified new strategies to help physicians predict which patients with advanced colorectal cancer may benefit from immunotherapy, according to a recent study published by Saberzadeh-Ardestani et al in Clinical Cancer Research. The findings demonstrate the potential of using...
New Data on a Response Biomarker for Dovitinib in Patients With RCC
A new report published by Knudsen et al in PLOS ONE focused on the clinical validation of a drug response predictor (DRP) biomarker algorithm for dovitinib, a receptor tyrosine kinase inhibitor of VEGFR1–3, PDGFR, FGFR1/3, c-KIT, FLT3, and topoisomerase 1 and 2. Data showed that the DRP-dovitinib...
DLBCL: Benefit From Polatuzumab Vedotin–Containing Regimens Based on Cell-of-Origin Subtype
In an analysis reported in a letter to the editor in The New England Journal of Medicine, Palmer et al identified evidence that polatuzumab vedotin-piiq–containing regimens were preferentially effective among patients with diffuse large B-cell lymphoma (DLBCL) with activated B cell (ABC) vs...
Improving Nutrition Guidance May Optimize Fertility Treatments for Female Cancer Survivors
Researchers have identified potential strategies to promote healthy dietary habits in female cancer survivors with fertility challenges, according to a recent study published by Klobodu et al in Integrative Cancer Therapies. Background Cancer may increase the risk of infertility in young female...
Risk Factors for Melanoma Among Individuals Living in Atlantic Canada
Investigators in Canada may have uncovered the factors contributing to the higher risk of melanoma among individuals living in Atlantic regions, according to a recent study published by Lagacé et al in Cancers. These findings may provide insights into effective strategies for skin cancer...
Updates on Cancer Therapies Under Study From 2023 ASCO Breakthrough
Presented here are some brief summaries of novel therapies under study from the 2023 ASCO Breakthrough meeting in Yokohama, Japan. The subjects range from new observations about a HER2-directed bispecific antibody and systemic treatment of gastric cancer to an option for treating hand-foot syndrome ...
Immunochemotherapy Triplet in Patients With Advanced Nonsquamous NSCLC and Untreated Brain Metastases
In a Spanish phase II study (Atezo-Brain; GECP17/05) reported in the Journal of Clinical Oncology, Ernest Nadal, MD, PhD, and colleagues investigated the activity of the combination of atezolizumab with chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) with...
Time Gaps May Be Critical Parameters When Sparing Skin During FLASH Radiation Therapy
Researchers have demonstrated that, in preclinical models, multiple beams and intervals in delivery during FLASH radiation therapy may compromise the skin-sparing effects of the technique, according to a novel study published by Mascia et al in the International Journal of Radiation Oncology •...
Edoxaban Taken for 12 Months May Improve Outcomes in Patients With Cancer and Isolated Distal Deep Vein Thrombosis
Researchers have found that 12 months of the oral factor Xa inhibitor edoxaban may be superior to 3 months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis, according to new findings presented by Yamashita et al at the European Society of Cardiology...
New Clinical Trial Seeks to Reduce Cardiovascular Damage in Patients Undergoing Anticancer Therapy for Breast Cancer
Researchers have launched a new clinical trial examining the effectiveness of behavioral and psychological interventions at reducing cardiovascular damage caused by anticancer therapies in patients with breast cancer. Background Breast cancer—the most common cancer type in the European...
How Is Administrative Payment Burden Associated With Cost-Related Delays in Cancer Care?
Research shows that the United States’ health-care delivery and financing system is so complex that streamlining administrative costs alone could reduce total health-care spending by 15%. In addition, health insurance payment and medical billing processes are time-consuming and expensive for both...
Ibrutinib Included Among the 10 Drugs Slated for Medicare Price Negotiations
On August 29, the Biden Administration announced the first 10 prescription medications that will be included in Medicare’s price negotiations with drug manufacturers as the government aims to reduce the financial burden on millions of older Americans and potentially save the Medicare program...
